Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA

Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA

SHANGHAI, HANGZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today...

Alphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer

Alphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer

SUZHOU, China, March 11, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the appointment of Dr. Hongwei Wang as Chief Technology Officer (CTO). Dr. Wang will be responsible for the company's Process Development and Analytical...

menu
menu